

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC
Form 8-K
May 04, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 4, 2004

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of incorporation)	000-23143 ----- (Commission File Number)	13-3379479 ----- (IRS Employer Identification No.)
--	---	---

777 Old Saw Mill River Road, Tarrytown, New York ----- (Address of principal executive offices)	10591 ----- (Zip Code)
---	------------------------------

Registrant's telephone number, including area code (914) 789-2800

(Former name or former address, if changed since last report.)

Item 7. Financial Statements and Exhibits

(c) Exhibits

Exhibit 99.1	Description Press Release dated May 4, 2004 (filed herewith).
--------------	--

Item 9. Regulation FD Disclosure.

On May 4, 2004, Progenics Pharmaceuticals, Inc. issued a press release announcing the initiation of a phase 1 clinical trial of its investigational drug PRO 140, a humanized monoclonal antibody viral-entry inhibitor, designed to prevent HIV (human immunodeficiency virus, the causative agent of AIDS) from

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

gaining access to healthy cells of the human immune system by blocking the CCR5 coreceptor, one of the principal portals HIV uses to enter cells. A copy of the press release is attached as Exhibit 99.1.

The information furnished pursuant to Item 9 in this Form 8-K shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no duty or obligation to publicly update or revise the information furnished pursuant to Item 9 in this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ PHILIP K. YACHMETZ

Philip K. Yachmetz
Vice President, General Counsel and Secretary

Date: May 4, 2004